公开(公告)号：WO2021194927A1

公开(公告)日：2021-09-30

申请号：PCT/US2021/023405

申请日：2021-03-22

申请人： TLC BIOPHARMACEUTICALS, INC. ,  TAIWAN LIPOSOME COMPANY, LTD.

发明人： TAI, Tien-Tzu ,  TSENG, Yun-Long ,  CHENG, Ting-Yu ,  SHIH, Sheue-Fang ,  CHEN, He-Ru ,  HONG, Keelung ,  FANG, Jonathan

IPC分类号： A61K9/00 ,  A61K9/127 ,  A61K31/4706 ,  A61K31/706 ,  A61P31/12 ,  A61K9/0078 ,  A61K9/1271

摘要： Provided is a composition of antiviral agent for use in prophylaxis or treatment against pathogenic infection. The liposomal antiviral agent of the composition has a liposome and an antiviral agent entrapped in the liposome. The antiviral agent has been stably encapsulated in the liposome, and the resulting liposomal antiviral agent is proven to be stably aerosolized or nebulized for administration via the inhalation route to treat a subject in need thereof with reduced side effect.

公开(公告)号：WO2022167536A2

公开(公告)日：2022-08-11

申请号：PCT/EP2022/052605

申请日：2022-02-03

申请人： KYME NANOIMAGING SRL

发明人： ROFFO, Felicia ,  TORINO, Enza ,  NETTI, Paolo Antonio

IPC分类号： B01J13/04 ,  A61K9/50 ,  A61K49/04 ,  A61K49/18 ,  C09B67/02 ,  A61K49/105 ,  A61K49/1812 ,  A61K49/1824 ,  A61K9/1271 ,  A61K9/1277 ,  C09B67/0097

摘要： A process for the preparation of self-assembled nanoparticles consisting of a lipid bilayer shell and an hydrogel core wherein active agents are entrapped by using a microfluidic device characterised in loading in the middle and sides channels of the microfluidic device a lipid stock solution, a solvent solution and a polymer solution, at specific concentrations and at a specific flow rate, to obtain the core-shell nanoparticles with desired features which can be used as contrast agents for multimodal imaging and in theranostic therapy.

公开(公告)号：WO2021258013A1

公开(公告)日：2021-12-23

申请号：PCT/US2021/038131

申请日：2021-06-18

申请人： AKAGERA MEDICINES, INC.

发明人： DRUMMOND, Daryl C. ,  TIPPARAJU, Suresh K. ,  NOBLE, Charles O. ,  KOSHKARYEV, Alexander ,  KIRPOTIN, Dmitri B.

IPC分类号： A61K31/422 ,  A61K31/4439 ,  C07D263/20 ,  A61K9/127 ,  A61K31/00 ,  A61K47/02 ,  A61K47/24 ,  A61K47/26 ,  A61K47/28 ,  A61K9/0019 ,  A61K9/1271 ,  A61K9/1277 ,  A61K9/1278 ,  A61P1/00 ,  C07D263/22 ,  C07D413/14

摘要： Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.

公开(公告)号：WO2021201310A1

公开(公告)日：2021-10-07

申请号：PCT/KR2020/004318

申请日：2020-03-30

申请人： 현대바이오사이언스 주식회사 ,  (주)위바이오트리

发明人： 김호준 ,  전용주

IPC分类号： A61K8/14 ,  A61K8/64 ,  A61K8/44 ,  A61K8/34 ,  A61K8/67 ,  A61K8/42 ,  A61Q7/00 ,  A61K31/16 ,  A61K31/355 ,  A61K31/375 ,  A61K8/11 ,  A61K8/553 ,  A61K8/673 ,  A61K8/676 ,  A61K8/678 ,  A61K9/1271 ,  A61K9/5015 ,  A61K9/5052 ,  A61P17/14

摘要： 본 발명은 비타민과 덱스판테놀이 봉입된 에토좀을 포함하는 에토좀 조성물로서, 상기 에토좀은 에탄올, 펩티드, 포스파티틸콜린(Phosphatidyl choline), 아미노산 화합물을 포함하는 에토좀 조성물 및 이의 제조방법에 관한 것이다. [대표도] 도6

公开(公告)号：WO2021191907A1

公开(公告)日：2021-09-30

申请号：PCT/IL2021/050336

申请日：2021-03-25

申请人： YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.

发明人： BARENHOLZ, Yechezkel ,  CERN, Ahuva ,  GOLDBLUM, Amiram

IPC分类号： A61K9/00 ,  A61K9/127 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4245 ,  A61K47/12 ,  A61K47/40 ,  A61K9/0019 ,  A61K9/1271

摘要： The present disclosure provides liposomal formulations comprising a lipid membrane comprising at least one liposome forming phospholipid and a sterol; and an intraliposomal aqueous compartment encapsulating at least one ATI receptor blocker (ARB) and a pH-dependent ionizable anion; with the liposomes having an effect upon administration to a subject in need of said effect, without causing a reduction in mean blood pressure of said subject of more than 50% as compared to the administration of the same amount of ARB in free form. The liposomes can be for systemic administration, e.g. by injection or for pulmonary administration, e.g. by inhalation.

公开(公告)号：WO2020081933A1

公开(公告)日：2020-04-23

申请号：PCT/US2019/056936

申请日：2019-10-18

申请人： TRANSLATE BIO, INC.

发明人： KARVE, Shrirang ,  PATEL, Priyal ,  VARGAS MONTOYA, Natalia ,  DEROSA, Frank

IPC分类号： A61K38/00 ,  A61K9/127 ,  A61K9/00 ,  A61K31/7105 ,  A61K9/0019 ,  A61K9/1271 ,  A61K9/1277

摘要： The present invention provides, among other things, a process of encapsulating messenger RNA (mRNA) in liposomes comprising a. providing a first stream comprising an mRNA solution at a first controlled flow rate, b. providing a second stream comprising a lipid solution at a second controlled flow rate, and c. mixing the first stream and the second stream to form mRNA-encapsulated liposomes, wherein the first controlled flow rate and the second controlled flow rate are achieved without use of a pump.

公开(公告)号：WO2023009976A1

公开(公告)日：2023-02-02

申请号：PCT/US2022/074102

申请日：2022-07-25

申请人： SUBHADRA, Bobban

发明人： SUBHADRA, Bobban

IPC分类号： A61K36/185 ,  A61K31/122 ,  A61K31/37 ,  A61K31/192 ,  A61K9/107 ,  A61K47/36 ,  A61K47/12 ,  A61P31/14 ,  A61K9/0043 ,  A61K9/1075 ,  A61K9/1271

摘要： The SARS-CoV-2 pandemic infected 504 million people with over 6.2 million deaths worldwide. Recent variants of SARS-CoV-2 are evolving faster and are more transmissible compared to the strain first reported. Broad-spectrum viral inhibitors that block the initial stages of infection by reducing virus binding and proliferation, thereby reducing disease severity is an unmet global medical need. A standardized polyphenolic-rich compound isolated from Pelargonium sidoides, against recombinant Vesicular Stomatitis Virus (rVSV)-pseudotyped SARS-CoV-2S (spike) of six different variants of SARS-CoV-2. Bi121 was effective in neutralizing all six rVSV-ΔG-SARS-CoV-2S variants expressing different mutations. The antiviral activity was then assessed against different variants of SARS-CoV-2 (USA WA1/2020, Hongkong/VM20001061/2020, B.1.167.2 (Delta)) and BA.1.1 (Omicron) in two different cell lines (Vero cells and HEK-ACE2) using RT-qPCR and plaque assays. Bi121 showed significant antiviral activity towards all the four SARS-CoV-2 variants tested, suggesting a broad-spectrum activity.

公开(公告)号：WO2022237466A1

公开(公告)日：2022-11-17

申请号：PCT/CN2022/087657

申请日：2022-04-19

申请人： 深圳市第二人民医院（深圳市转化医学研究院）

发明人： 顾大勇 ,  高成 ,  徐勇 ,  陈曦 ,  张健 ,  周洪钟

IPC分类号： A61K9/127 ,  A61K47/46 ,  A61K35/748 ,  A61K47/69 ,  A61P35/00 ,  A61J3/00 ,  A61K47/60 ,  A61K47/6949 ,  A61K47/6951 ,  A61K9/1271 ,  A61K9/1278

摘要： 一种载药系统及其制备方法、药物组合物。该载药系统包括载体、由细胞膜制成的囊泡和包埋于所述囊泡中的蓝藻，载体包括载药部和与载药部连接的嵌膜部，嵌膜部嵌于囊泡上，载药部位于囊泡外。载药系统具有良好的生物相容性、靶向递送性和产氧长效性，能够改善缺氧组织所用的供氧材料产氧时间短而需要不间断给药的问题。

公开(公告)号：WO2021226597A2

公开(公告)日：2021-11-11

申请号：PCT/US2021/031629

申请日：2021-05-10

申请人： ORNA THERAPEUTICS, INC.

发明人： GOODMAN, Brian ,  WESSELHOEFT, Alexander ,  HORHOTA, Allen T. ,  YANG, Junghoon ,  OTT, Kristen ,  BARNES, Thomas

IPC分类号： A61K48/00 ,  A61K31/7088 ,  C12N15/115 ,  C12N15/64 ,  A61K31/7105 ,  C07K14/725 ,  C12N15/85 ,  C12N15/11 ,  A61K9/00 ,  A61K9/127 ,  A61K31/713 ,  A61K39/00 ,  A61K39/39 ,  C12N15/113 ,  C12N15/88 ,  A61K2039/5156 ,  A61K2039/572 ,  A61K39/0011 ,  A61K39/001112 ,  A61K39/001117 ,  A61K39/001124 ,  A61K48/0008 ,  A61K48/0041 ,  A61K48/005 ,  A61K9/0019 ,  A61K9/1271 ,  A61K9/1272 ,  A61P35/00

摘要： Disclosed herein are circular RNAs and transfer vehicles, along with related compositions and methods of treatment. The circular RNAs can comprise group I intron fragments, spacers, an IRES, duplex forming regions, and/or an expression sequence, thereby having the features of improved expression, functional stability, low immunogenicity, ease of manufacturing, and/or extended half-life compared to linear RNA. Pharmaceutical compositions comprising such circular RNAs and transfer vehicles are particularly suitable for efficient protein expression in immune cells in vivo. Also disclosed are precursor RNAs and materials useful in producing the precursor or circular RNAs, which have improved circularization efficiency and/or are compatible with effective circular RNA purification methods.

公开(公告)号：WO2021222903A2

公开(公告)日：2021-11-04

申请号：PCT/US2021/030495

申请日：2021-05-03

申请人： PHAM, Randal Tanh Hoang ,  BERNSTEIN, Eric F. ,  KOOP, Dale

发明人： PHAM, Randal Tanh Hoang ,  BERNSTEIN, Eric F. ,  KOOP, Dale

IPC分类号： A61K39/395 ,  A61K9/127 ,  A61K41/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61K39/3955 ,  A61K47/6929 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/1271 ,  C07K16/22 ,  C07K2317/24

摘要： A composition for treating abnormal or excessive angiogenesis, such as pyogenic granuloma comprising an anti-vascular endothelial growth factor (anti-VEGF) agent (e.g., an antibody or small molecule inhibitor of VEGF signaling) and a carrier comprising nanoparticles. Methods of treating abnormal or excessive angiogenesis by administering a composition comprising an anti-VEGF agent and nanoparticles, alone or in combination with administering an anti-inflammatory steroid, and administering a non-steroidal anti-inflammatory drug (NSAID) to a subject. Devices for administering the composition for treating pyogenic granuloma are also disclosed.